Sanguinate

Sanguinate is a dual-action, investigational biopharmaceutical product composed of purified bovine hemoglobin that has been pegylated and combined with carbon monoxide. It functions as both a carbon monoxide-releasing molecule and an oxygen transfer agent, designed to deliver oxygen to hypoxic tissues while also releasing therapeutic levels of carbon monoxide. This dual mechanism aims to treat conditions characterized by ischemia or hypoxia, such as sickle cell disease (including vaso-occlusive crisis), acute ischemic stroke, delayed cerebral ischemia after subarachnoid hemorrhage, and other disorders involving inflammation and reperfusion injury. Sanguinate improves microvascular perfusion, reduces vasoconstriction and inflammation, and may help restore flow-metabolism balance in vulnerable brain regions. Developed by Prolong Pharmaceuticals, it has received FDA orphan drug designation for sickle cell disease and Fast Track designation for acute ischemic stroke[1][4][5][6][8].

Brand names

Sanguinate

Other names

PEGylated carboxyhemoglobin bovinePEGylated-carboxyhemoglobin-bovine